Purpose Systemic measures of chronic inflammation, often based on a single blood draw, are frequently used to study the associations between inflammation and chronic diseases such as cancer. However, more information is needed on the measurement error in these markers due to laboratory error, within-person variation over time, and long-term storage.
Introduction
C-reactive protein (CRP), an acute-phase reactant, and proinflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-a) have been implicated in the development as well as progression of a variety of human diseases, such as cancers [1] [2] [3] , cardiovascular disease [4, 5] , and diabetes [6] . Typically, studies investigating the association of inflammatory biomarkers on subsequent risk of chronic diseases utilize established cohorts with repositories of biological specimens collected prospectively, since biomarker levels will often be modified after disease diagnosis. Therefore, specimens will often be stored for 10 years or more before laboratory analysis. Additionally, in most studies, biological samples collected for analyses are limited in quantities, and only a single biospecimen per participant may be available for analysis. Although numerous epidemiological studies have used cytokine measurements from a single blood draw as their primary exposure, it is uncertain whether a single measure of an inflammatory biomarker is reflective of an individual's average level over time. The current evidence surrounding the reliability and intraindividual variability of inflammatory biomarkers is primarily restricted to studies involving CRP and IL-6 [4, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . The existing studies are limited by small sample sizes [7, 9, 10, 12-16, 18, 20, 22] and most evaluate the within-person variability over a relatively short period of few weeks to a year [8, 9, 13, 15, [18] [19] [20] 22] . Moreover, they typically involve healthy participants with considerably lower (and sometimes undetectable) blood levels of cytokines thus having to deal with missing data. None of these existing studies have evaluated the effect of long-term storage of blood samples on their reliability.
In this report, we analyzed the intraindividual variability of biomarkers of inflammation including CRP, IL-6, soluble tumor necrosis factor receptor I (sTNF-RI), and soluble tumor necrosis factor receptor II (sTNF-RII) in a subset of the Seattle Barrett's esophagus study (SBES), a large prospective cohort of Barrett's esophagus patients being followed to development of esophageal adenocarcinoma. In addition, we assessed the laboratory error and the effects of long-term storage of blood samples of these biomarkers. The biomarkers studied in this report are those that were simultaneously being evaluated for their association with esophageal adenocarcinoma, as part of separate analyses.
Materials and methods

Study population
The parent study, the Seattle Barrett's esophagus study (SBES), is an ongoing prospective cohort study designed to identify predictors of neoplastic progression in Barrett's esophagus that may assist in risk stratification, screening, and surveillance. It is comprised of persons with an established histological diagnosis of Barrett's esophagus with no history of esophageal cancer. The details involving cohort recruitment, baseline protocol, and follow-up procedures have been described previously [23, 24] . Briefly, at the baseline visit, participants underwent an extensive personal interview, dietary and anthropometric assessments, and provided blood samples in addition to an endoscopy with biopsy as per a standard cancer surveillance protocol [25, 26] . At subsequent follow-up visits, shorter personal interviews were completed by the participants, and blood and biopsy samples were collected. Biomarkers of interest were measured at the first two time points with available blood samples (baseline and first follow-up visits for most). The median duration between the two visits was 1.8 years (IQR 1.3-2.0 years). The Institutional Review Boards at the University of Washington and Fred Hutchinson Cancer Research Center approved the study.
A total of 427 participants were enrolled in the SBES cohort between February 1, 1995 and September 30, 2009, 411 of whom had at least one follow-up visit completed at the time of present data analysis. Of the 411, 51 participants had either exhausted their stored blood or had blood specimens available only at a single time point. Hence, for the purposes of the current report, we used plasma measurements of inflammation markers from the remaining 360 participants. In addition, 31 individuals had one or both of their plasma CRP levels greater than 10 mg/l and hence were omitted from the CRP analysis due to an a priori hypothesis that levels over 10 mg/l are indicative of acute inflammation and should be excluded from the reliability study, as they would be from the parent study. Thus, we used plasma CRP measures from 329 participants while all 360 participants' biomarker measurements for IL-6, sTNF-RI and sTNF-RII were utilized for data analysis.
Laboratory methods for biomarker assessment
Fasting venous blood samples were obtained from each participant, processed within 2 h after collection and stored at -80°C until analysis. Plasma levels of CRP were measured at the Research Testing Services laboratories at the University of Washington Medical Center, Seattle, WA; while all other cytokines were measured at the PHS Biomarker lab at the Fred Hutchinson Cancer Research Center, Seattle, WA. CRP and IL-6 assays were conducted on never-thawed plasma samples, while once-thawed samples were used for the sTNF receptors measurement. Plasma CRP concentrations were determined with a highsensitivity assay using immunonephelometry (Dade Behring Inc, Deerfield, IL, USA) as per the manufacturer's instructions. The minimum detectable limit for this assay was 0.2 mg/l for CRP; a mid-range value of 0.1 mg/l was assigned to values below the detection limit (\1 % samples). Plasma levels of IL-6 were assayed using the Quantikine HS human IL-6 Elisa kit (R&D Systems Inc, HS600B) according to the manufacturer's instructions. The limit of quantification for this assay was 0.156 pg/ml, and none of the samples were below this level. For every participant, IL-6 samples were run in duplicate and averaged, with a median duplicate coefficient of variation (CV) of 2.7 %; samples with CVs greater than 12 % were re-run in duplicate, and the two new measurement values were used for analysis after averaging the duplicate values. sTNF-RI and sTNF-RII were measured using the MILLIPLEX MAP Human Soluble Cytokine Receptor Panel (Millipore, Billerica, MA, HSCR-32K) according to the manufacturer's instructions. The limit of quantification for the Millipore assay was 12.2 pg/ml, and all the samples were over this limit. Similar to IL-6, samples were run in duplicate with a median duplicate CV of 4.11 % for sTNF-RI and 3.37 % for sTNF-RII; samples with CVs greater than 12 % were re-run, and the re-run values were used for analyses. For every individual, the two samples from different time points were run in the same batch for laboratory analysis thus limiting our capability to estimate betweenbatch error in the ICCs.
In addition to the quality control procedures conducted by the laboratories, we included aliquots of a blinded pooled plasma sample in every batch of study samples analyzed (two aliquots per IL-6 and sTNF receptor batches, one aliquot with every CRP batch). Intra-and inter-batch CVs were calculated based on the measurements from these blinded aliquots.
Statistical analyses
Median levels of the various biomarkers studied were computed at each of the two time points along with their interquartile ranges. To assess the laboratory component of error, we estimated the intra-and inter-batch CVs for IL-6 and sTNF receptors and inter-batch CVs for CRP using the blinded pooled plasma specimens included with each batch of study samples. CVs were calculated as 100 times the ratio of the SD (r) to the mean (l) and expressed as a percentage; CV = 100 9 r/l. ICCs and their 95 % confidence intervals (95 % CIs) were calculated to evaluate the total measurement error including variation within individuals over time, using random effects analysis of variance (ANOVA) models. The within (r W 2 )-and between (r B 2 )-subject variance from the ANOVA models was used to compute the ICCs using the formula ICC = r B 2 / (r B 2 ? r w 2 ) [27] . Following Rosner's definitions of reliability, ICCs C 0.75 were considered to indicate excellent correlation, 0.4 B ICCs \ 0.75 were considered to be indicative of fair-to-good correlation, and ICCs \ 0.4 were indicative of poor reproducibility [28] . Additionally, the ICC analyses were repeated after stratifying by duration between the two samples (B2 years, [2 years) as well as by the storage time of the earlier of the two samples (i.e., longest stored sample) used for ICC calculation (B13 years, [13 years) to evaluate whether long-term storage affected the repeatability of these inflammation markers. The cutpoints for the stratified analyses were based on the mean values for the duration between the two samples and the mean storage time of the earlier of the two samples, respectively. Finally, we evaluated whether the actual median biomarker values of the longest stored of the two samples varied with storage time by conducting regression analyses and likelihood-ratio tests for each biomarker, and estimating the two-sided p value associated with the biomarker when treated as a grouped linear variable. The ICC computations were completed using the STATA version 12.0 statistical software (StataCorp LP, College Station, Texas, USA).
Results
The baseline-descriptive characteristics of our study sample are summarized in Table 1 . The median age of the study participants was 61 years (IQR 53-69 years) and majority were males (82.2 %). A large proportion (40 %) of the study participants were obese, i.e., body mass index (BMI) greater than 30 kg/m 2 , with 10 % having a BMI over 35 kg/m 2 . The median waist-hip ratio for the study participants was 0.95 (IQR 0.91-0.99).
The intra-and inter-batch CVs estimating assay precisions based on the blinded pooled plasma samples are reported in Table 2 . As we included only one blinded pooled sample with every CRP batch, we were unable to report the intra-batch variability in CRP measurements. CVs for intra-batch variation for the different assays ranged from 2.4 to 5.9 % while those for inter-batch variation were between 2.9 and 8.9 %. Low CVs are indicative of less dispersion from the mean and therefore better reproducibility.
The medians and the interquartile ranges of the various cytokines at the two time points are reported in Table 3 . The higher the ICC for an inflammation marker, the greater the proportion of total variation in that marker can be attributed to actual differences between individuals, rather than intraindividual variability or laboratory error. We further evaluated the reliability of these cytokines after stratification by the duration between two time points at which blood samples were collected as well as by the duration the first (earliest) of the two samples was stored ( Table 3 ). The mean duration between the two blood samples used for biomarker measurements was 1.8 years (range 0.3-8.8 years). Hence, we used a cutoff of 2 years to stratify the duration between two samples. The ICC values for the two subsets stratified by duration between the two samples were similar for most of the biomarkers (The ICCs for sTNF-RII appeared to differ by duration between samples, but it is unlikely that reliability can be better over longer duration). The average storage time for the earlier of the two samples analyzed was 12.5 years (range 2.3-15.4 years) for CRP and 12.6 years (range 2.5-15.5 years) for IL-6 and sTNF receptors. We used a cutoff of 13 years to stratify storage time for the longest stored samples used for analyses. The average storage time for samples stored B13 years was 9.4 years (range 2.3-13 years) while that for samples stored [13 years was 14.2 years (range 13-15.5 years). The ICCs for CRP and IL-6 appeared to differ with storage time such that ICCs were lower when at least one of the two samples was stored for more than 13 years [ICC CRP, storage [13 years = 0.50 We also evaluated whether the median biomarker levels for the longest stored sample varied by storage duration.
The median values of all the biomarkers at four separate storage time categories (B10,[10 to B13,[13 to B14, and [14 years) are displayed in Table 4 . As seen in Table 4 , there was no apparent trend in biomarker levels with increasing storage time, suggesting that the median values of the biomarkers were stable across storage times (at -80°C), even though there was increased within-person variability with long-term storage as shown in Table 3 .
Discussion
In this methodologic study, we evaluated the intraindividual variability of inflammation markers CRP, IL-6, sTNF-RI, and sTNF-RII over 1.8 years on average, in a subsample of the SBES cohort. Comparing the biomarker concentrations at the first two available plasma samples during follow-up (usually baseline and first follow-up), we observed that the ICCs for CRP and IL-6 were fair-to-good while those for sTNF-RI and TNF-RII were excellent, as per the criteria described by Rosner [28] . We also observed that the ICCs for sTNF-RI and sTNF-RII did not differ by storage time, while those for CRP and IL-6 were lower among those participants that had at least one of the two samples stored for over 13 years, as compared to study participants with both samples stored for less than 13 years. To our knowledge, this is the first study to examine the effects of longterm storage of blood samples on the intraindividual variability and reliability of inflammation markers. Overall, these data suggest that long-term storage of blood samples may impact the reliability of some biomarkers as shown by the lower ICCs for CRP and IL-6 with storage over 13 years, while other biomarkers may be largely unaffected by prolonged storage, e.g., sTNF receptors. Hence, in epidemiological studies of longer duration, it is essential to understand the variability of the biomarkers under consideration before drawing conclusions.
The overall ICCs reported in our study are fairly consistent with those reported by previous studies. Numerous studies have examined the intraindividual variability of CRP measurements, with reported ICCs between 0.58 and 0.76 over a wide range of time between blood draws (2 weeks to 12 years) [4, 7, 8, 10, 11, 14, [18] [19] [20] [21] . The ICC for CRP in our study (0.55), although slightly lower than those reported in the past, is still indicative of good CV coefficient of variation, CRP C-reactive protein, IL-6 interleukin-6, sTNF-RI surface tumor necrosis factor receptor I, sTNF-RII surface tumor necrosis factor receptor II reproducibility. The ICC values for IL-6 reported in the literature are highly variable with studies reporting values as low as 0.37 [9] to as high as 0.92 [14] , with most values in the range of 0.5-0.8 [10, 12, 15, 16, 18, 20, 22] . We reported an ICC value of 0.57 for IL-6 which is suggestive of good reproducibility. Only four studies have reported on the reliability of sTNF receptors [10, 12, 14, 20] , and the sample sizes of three of them were much smaller (n B 65) as compared to our study. Our findings regarding ICCs of sTNF receptors I and II (0.89 and 0.85, respectively) are similar to those by Navarro et al. (ICCs of 0.92 and 0.90 for sTNF-RI and sTNF-RII, respectively) and suggest excellent reproducibility of sTNF receptors. Our estimates for sTNF receptors are higher than those reported by the other three studies [10, 12, 14] . However, they used a kit different from the one we used for the estimation of sTNF receptor status, which may have contributed to the difference.
In most large-scale prospective epidemiological studies, enrollment into the study, data collection, and follow-up may span over several years; in some studies, like ours, it may even span over decades. Such studies rely on their biological banks where samples are stored for multiple years before analysis. It is, therefore, important to understand the effects of long-term storage of biological samples on their reliability, a question that is, to our knowledge, as yet unexplored with respect to markers of inflammation. We examined ICCs of the inflammation markers after stratifying on the duration of the longest stored sample (i.e., the first of the two samples analyzed for every individual) and found that even after more than 13 years of storage, the ICCs suggested good-to-excellent reproducibility. There was no difference in the ICCs for the sTNF receptors between the two groups, suggesting that these markers were largely unaffected by the duration of storage. ICCs for CRP and IL-6 decreased somewhat for the group with over 13 years of sample storage (CRP 0.50, IL-6 0.51) as compared to the group with less than 13 years of storage (CRP 0.64, IL-6 0.67).
To assess whether there was any systematic degradation in actual serum biomarker levels over storage time, we examined the median biomarker levels for the earlier of the two samples collected. We did not find any evidence of a statistical trend in the biomarker levels with increasing storage time. Our results suggest that there is some concern regarding increased variability (i.e., lower repeatability as measured by ICCs) for CRP and IL-6 over prolonged storage; however, there does not seem to be any systematic increase or decrease in the actual biomarker levels over storage time.
In addition to estimating the ICCs, we also evaluated the amount of laboratory measurement error or batch-to-batch variability in inflammation marker measurements by including blinded pooled plasma samples with every batch of biomarker analyzed. Little variability was found in the inflammation marker measurements in pooled aliquots within as well as between the different batches. The intraand inter-batch CVs for the blinded pooled plasma samples were low (range 2.4-8.9 %), indicative of good reproducibility of the assays with low batch-to-batch variation.
One strength of our study is that the ICCs computed in our study were able to capture most sources of error that affect epidemiologic studies using these biomarkers: the laboratory error, the field procedures error, e.g., due to variations in how specimens were collected, some amount of storage error as well as individual variation over time. The only error that we were unable to capture as a part of our ICCs is the batch-to-batch error, as samples from the same individual were tested in the same batch; however, that error is measured by the inter-batch CV.
Our study has a number of other strengths, the most important one being its large sample size. To date, this is the largest study assessing the intraindividual variability of the sTNF receptors. Additionally, it is the first study to evaluate the effects of long-term storage of blood specimens on the reliability of inflammation markers. Another strength of our study is the use of never-thawed samples for most biomarker measurements and minimal processing times (\2 h) after blood collection, both of which minimize the coefficient of variation and the laboratory error. This is particularly important for cytokines due to the concern of ex vivo expression of cytokines from leukocytes due to prolonged blood-processing times after collection [29] . Both strength as well as a limitation of our study was a large proportion of obese individuals (40 %) in the cohort. The study participants might have had elevated levels of inflammation markers as compared to the general population due to their obesity [30] . On the one hand, this was beneficial as, unlike many of the previous studies, we did not encounter the problem of a large proportion of biomarkers being below detection limit. On the other hand, the high ICCs observed in this report may have been the result of a higher variation in the biomarker levels of the cohort, due to a higher proportion of obese individuals [31, 32] . Another limitation of our study was that all the participants in our cohort had Barrett's esophagus and hence our results may not be readily generalizable to other populations. In addition, we were unable to assess the effects of shorter-term storage on markers of inflammation. Some reports have suggested a possible degradation of samples within 2-5 years of storage [33] [34] [35] , even with storage temperatures of -70°C or below, for various cytokines. However, in our study, only 15 % of samples were stored for less than 10 years, limiting our ability to assess either the within-person variability of samples stored for less than 10 years or any trend in median values due to degradation of samples over the first 10 years. Further studies are needed to evaluate the stability of measures of inflammation over the first decade of storage, ideally comparing measures on the same individuals from fresh blood and periodically over the first 10 years of storage.
In conclusion, we observed that biomarkers of CRP and IL-6 have moderate variability over time within person, and appear to be affected by prolonged storage of blood samples, while biomarkers of sTNF receptors vary little within person over time and are largely unaffected by longterm blood storage. Hence, in epidemiological studies of prolonged duration involving CRP or IL-6, methods to reduce this variability should be considered such as averaging multiple measures over time.
